SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (378)1/8/2003 6:40:27 PM
From: keokalani'nui  Read Replies (3) of 598
 
Here is what I heard as new or noteworthy. Slides were not webcast.

1. 2 years cash

2. Expect active partnering in 2003

3. 13 advanced leads.

4. 1-2 new IND’s 2003. To me that meant in addition to CXCR3 and Pparg.

5. 2 collaborator’s drugs in P1, Merck HIV integrase and Lilly Fxa.

6. 1 JT/tlrk JV IND candidate metabolic.

7. t67 p3 starts 1Q03. After first 100 patients, ALL parameters analyzed by DSMB.

8. T607 studies complete 3Q03, figure out what to pursue then.

9. CXCR3 “Essentially no SEs of any time in P1.” Multi dose Proof of concept P2 in RA and psoriasis starts in 4Q03.

10. T131. Reviewed how it is similar but structurally distinct from other TZDs, producing conformational differences. P1 healthy patients this month dose escalation. P2 in T2 diabetics 4Q03.

11. 1-2 new INDs 2003. Mentioned lipid/HDL and 2 obesity drugs, one CNS and one GI.

12. Discussing new collaborations with a number of big pharma.

13. 2003 burn $100m. Expect active partnering.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News